Immunogenetics

CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Tuesday, October 17, 2023
Science, Biotechnology, Research, Surgery, Health, Health Technology, Genetics, Clinical Trials, Standard of care, Abstract, Paris Institute of Statistics, Society, Laboratory for Experimental Medicine and Surgery in Primates, Parameter, University of Utah, NGS, Assistant, HLA, LIMS, Standard, Caregiver, University, Histocompatibility, Laboratory information management system, St Paul's Cathedral, Chimera, Doctor of Philosophy, ACHI, Kidney transplantation, Biomarker, Laboratory, Patient, Management, Dentistry, Transplant, Nephrology, MD, Immunogenetics, Medicine

These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.

Key Points: 
  • These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.
  • The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies.
  • Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.
  • Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR.

Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets

Retrieved on: 
Friday, May 12, 2023
Allergy, Antigen, Food, GC/MS, Immunogenetics, Health, Genetics, HLA, Transfusion medicine, Allele, NGS, Shimadzu, Personalized medicine, AB, Thermo Fisher Scientific, Element, Danaher Corporation, Science, Patient, Risk, Organ transplantation, Algorithm, Immune system, Cancer, Medicine, Agilent Technologies, Diagnosis, Waters Corporation, Research, LC/MS, Mindful Scientific Inc., Safety, Dentistry, Vaccine, Medical imaging

Life Science Instrumentation Market Advantages:

Key Points: 
  • Life Science Instrumentation Market Advantages:
    Improved Organ Transplantation Success: Accurate Life Science Instrumentation plays a critical role in organ transplantation.
  • Rapid Technological Advancements: The Life Science Instrumentation market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms.
  • Overall, the Life Science Instrumentation market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress.
  • These advantages contribute to the growing importance and widespread utilization of Life Science Instrumentation in the field of healthcare.

Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets

Retrieved on: 
Friday, May 12, 2023
Allergy, Antigen, Food, GC/MS, Immunogenetics, Health, Genetics, HLA, Transfusion medicine, Allele, NGS, Shimadzu, Personalized medicine, AB, Thermo Fisher Scientific, Element, Danaher Corporation, Science, Patient, Risk, Organ transplantation, Algorithm, Immune system, Cancer, Medicine, Agilent Technologies, Diagnosis, Waters Corporation, Research, LC/MS, Mindful Scientific Inc., Safety, Dentistry, Vaccine, Medical imaging

Life Science Instrumentation Market Advantages:

Key Points: 
  • Life Science Instrumentation Market Advantages:
    Improved Organ Transplantation Success: Accurate Life Science Instrumentation plays a critical role in organ transplantation.
  • Rapid Technological Advancements: The Life Science Instrumentation market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms.
  • Overall, the Life Science Instrumentation market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress.
  • These advantages contribute to the growing importance and widespread utilization of Life Science Instrumentation in the field of healthcare.

CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference

Retrieved on: 
Tuesday, April 25, 2023
Science, Other Science, Research, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, Experience, Immunogenetics, HLA, Nucleic acid thermodynamics, Histocompatibility, UTR, NGS, Platinum, MicroRNA, Chimera, Ambiguity, Teaching hospital, Regulation, Patient, Necker–Enfants Malades Hospital, National Institute of Allergy and Infectious Diseases, Medicine, Risk assessment, Hospital, Massive parallel sequencing, Phenotype, Conference, Caregiver, Pharmaceutical industry, Dentistry, Medical device, EU

“We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • “We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx.
  • For post-transplant, CareDx offers AlloSeq HCT* chimerism testingand AlloSeq cfDNA* for labs to assess transplanted stem cells and organ health, respectively.
  • CareDx also provides pre-transplant HLA typing and post-transplant surveillance testing for customers through its service lab in Stockholm, Sweden, for clinical research.
  • CareDx will sponsor a symposium “Breaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes” on Thursday, April 27.

Sonata Therapeutics Strengthens Leadership Team with Appointment of Francesco Marincola, M.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, March 21, 2023
Society, Drug development, University, Therapy, Senior, Stanford University, CSO, Cancer, Infection, SITC, Immunotherapy, Sidra Medical and Research Center, Research, Cell, Practice, Bangladesh Technical Education Board, Immunogenetics, National Cancer Institute, Society for Immunotherapy of Cancer, AbbVie, Bone marrow, Neoplasm, University of Milan, Kite Pharma, NCI, NIH, Pharmaceutical industry, Sonata

WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Sonata Therapeutics Inc., a biotechnology company creating therapeutics that transform diseased cells into coordinators of cure, today announced the appointment of Francesco Marincola, M.D., as Chief Scientific Officer.

Key Points: 
  • WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Sonata Therapeutics Inc., a biotechnology company creating therapeutics that transform diseased cells into coordinators of cure, today announced the appointment of Francesco Marincola, M.D., as Chief Scientific Officer.
  • “We are excited to welcome Franco to Sonata as its new CSO,” said Volker Herrmann, M.D., President and Chief Executive Officer of Sonata.
  • “Throughout his successful career across academia and industry over the last few decades, Franco has stood at the forefront of discovery and drug development.
  • Prior to Kite, he held numerous industry roles, including President and Chief Scientific Officer at Refuge Biotechnologies, Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.

Devyser Diagnostics AB: New more sensitive diagnostics protect transplanted kidney

Retrieved on: 
Thursday, March 9, 2023
Transplant, Clinical chemistry, Blood, Dialysis, CKD, Chronic kidney disease, Antibody, DNA, Patient, Kidney transplantation, Risk, Lymphocyte, Medicine, Immune system, Survival, Urine, Immunogenetics, Conference, Creatinine, Acute kidney injury, Kidney, National Academy of Medicine, Histocompatibility, Dentistry, Pharmaceutical industry

With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier, and proper treatment introduced to protect the kidney.

Key Points: 
  • With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier, and proper treatment introduced to protect the kidney.
  • The goal of new more sensitive diagnostics is to increase the survival of the new organ and reduce the need for new transplantation.
  • (1) A major problem associated with kidney transplantation is the risk of damage or kidney loss.
  • The most common causes for this are rejection, surgical complications, or other kidney damage by for instance immunosuppressive drugs.

Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure

Retrieved on: 
Tuesday, November 8, 2022
Tinnitus, Nasal spray, Medical research, Transplant, Risk, Person, Therapy, Exercise, Securities Exchange Act of 1934, Virus, Company, Cell, Drug Quality and Security Act, Connective tissue, Immunogenetics, Forward-looking statement, IAAI, Nose, Fraunhofer Society, Food, Pollen, Securities Act of 1933, HPMC, Toxicology, RNA, SEC, Rhinitis, Patient, COVID-19, Allergen, Nasdaq, NASAR, Achievement, Allergic rhinitis, Allergy, Terminology, ANCOVA, Baháʼí World Centre buildings, ITEM, FDA, House, OTC, Nasal mucosa, Karger Publishers, U.S. Securities and Exchange Commission, Hearing loss, Securities & Exchange Commission of Pakistan, Annual report, Peer review, US Foods, NASDAQ, Safety, Vertigo, Journal, Pharmaceutical industry, Vaccine, Immunology

The trial showed that BentrioTM (AM-301) alleviated allergic nasal symptoms during controlled exposure to grass pollen for four hours.

Key Points: 
  • The trial showed that BentrioTM (AM-301) alleviated allergic nasal symptoms during controlled exposure to grass pollen for four hours.
  • As previously announced, the Company is seeking to divest or out-license Bentrio for key markets in North America and Europe.
  • Bentrio showed a persisting protective effect over the four hours of pollen exposure, which was in line with the other tested barrier-forming nasal spray.
  • Bentrio showed significantly lower increases in the TNSS than HPMC during the first 40 minutes of pollen exposure.

CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Tuesday, October 25, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical Trials, Diamond, Caregiver, Doctor of Philosophy, SEC, ABB, Annual report, Society, Patient, Transplant, Nasdaq, Time, Precision medicine, Histocompatibility, The Meeting, NGS, Genetic distance, CEO, 2021 Essex County Council election, Hematopoietic stem cell transplantation, ACHI, Solution, HLA, Pharmaceutical industry, Immunogenetics, Research

CareDx is proud to be a leading sponsor of this years ASHI meeting to help drive continued innovation in transplantation through our laboratory products, said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • CareDx is proud to be a leading sponsor of this years ASHI meeting to help drive continued innovation in transplantation through our laboratory products, said Reg Seeto, CEO and President of CareDx.
  • Moderated by Curtis Lind, Vice President and Head of Research and Development Products at CareDx, the symposium includes the following:
    NGS-HLA for Solid Organ Transplant: The Time is Now.
  • Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI), Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.
  • Eight scientific abstracts highlight the use of CareDxs flagship AlloSeq Tx171, which offers laboratory professionals a novel method for matching transplant recipients and potential donors.

Immucor and Pirche announce multi-year partnership

Retrieved on: 
Tuesday, October 4, 2022
Histocompatibility, HLA, CEO, Risk assessment, MIA, Partnership, Molecular medicine, Quality of life, Transplant, Patient, Laboratory, Society, GLOBE, Medical device, Vaccine, Dentistry, Immunogenetics, Georg Dubislav Ludwig von Pirch

Immucor will also make an investment in Pirche as part of this partnership.

Key Points: 
  • Immucor will also make an investment in Pirche as part of this partnership.
  • Immucor announced their goal to provide users a seamless and direct interface with the Pirche epitope matching prediction pipeline in their transplant analysis software.
  • The establishment of our partnership with Pirche will allow transplant histocompatibility laboratories the option to integrate their data with PIRCHE easily, said Avi Pelossof, Immucors President and CEO.
  • Immucor and Pirche will share their latest innovations at the 48th annual meeting of The American Society for Histocompatibility and Immunogenetics (ASHI).

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

Retrieved on: 
Tuesday, September 13, 2022
ASX, Institut Gustave Roussy, Institute, Autoimmune disease, Australian Securities Exchange, Publication, University of Paris, Antibody, Acquisition, IMM, Immunotherapy, Â, Patient, Cancer, Technology, NASDAQ, Board, GLOBE, PD-1, Immunogenetics, Russell, APC, IGR, Pharmaceutical industry, Vaccine, Immunology, Immutep, LAG-3

Prof. Triebel will join the Immutep Board with immediate effect.

Key Points: 
  • Prof. Triebel will join the Immutep Board with immediate effect.
  • He founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Companys acquisition of Immutep S.A in December 2014.
  • Immutep Chair, Russell Howard said: It is a privilege to welcome Frdric to Immuteps Board.
  • I look forward to working as part of the Board to realise the value of this promising product candidate.